Processa Pharmaceuticals (PCSA) Director Geraldine Pannu Receives Award

What Happened
Geraldine Pannu, a director of Processa Pharmaceuticals (PCSA), received a grant of 33,500 restricted stock units (RSUs) on July 26, 2026. The filing reports the acquisition at $0.00 (transaction code A — award/grant). The RSUs vested upon grant but, per the filing, will not be distributed immediately.

Key Details

• Transaction date: 2026-07-26; Form 4 filed: 2026-07-28 (filed within the typical two-business-day window).
• Grant size: 33,500 RSUs; reported acquisition price: $0.00 (derivative award).
• Shares owned after transaction: not specified in the filing.
• Footnote F1: Each RSU represents a contingent right to one share; RSUs vested on grant but will be distributed only upon the earliest of (i) termination, (ii) six-month anniversary of grant, (iii) change of control, or (iv) death.
• Footnote F3: Reported amounts reflect the 1-for-25 reverse stock split effective Dec 17, 2025.
• Transaction code meaning: A = Award/Grant (derivative); this is compensation, not an open-market purchase or sale.

Context
RSUs are a form of equity compensation and, while these units vested immediately, the shares will not be issued to Pannu until a future distribution event per the footnote conditions. This grant is a compensation-related insider transaction and does not directly indicate a buy or sell decision by the director.